8-K
LEMAITRE VASCULAR INC (LMAT)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 29, 2021
LeMaitre Vascular, Inc.
(Exact name of registrant as specified in its charter)
Commission File Number: 001-33092
| Delaware | 04-2825458 |
|---|---|
| (State or other jurisdiction of | (IRS Employer |
| incorporation) | Identification No.) |
63 Second Avenue
Burlington, MA 01803
(Address of principal executive offices, including zip code)
781-221-2266
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by checkmark whether the company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12c-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Exchange Act:
| Title of each class | Trading symbol | Name of exchange on which registered |
|---|---|---|
| Common stock, $0.01 par value per share | LMAT | The Nasdaq Global Market |
Item 2.02. Results of Operations and Financial Condition.
On April 29, 2021, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended March 31, 2021. A copy of the press release is furnished as Exhibit 99.1 to this Report.
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
| The following exhibits are furnished or filed as part of this Report, as applicable: | |
|---|---|
| (d) | Exhibits. |
| --- | --- |
| Exhibit No. | Description |
| --- | --- |
| 99.1 | Press release issued by LeMaitre Vascular, Inc. on April 29, 2021. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Exhibit Index
| Exhibit No. | Description |
|---|---|
| 99.1 | Press release issued by LeMaitre Vascular, Inc. on April 29, 2021. |
Signature(s)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LeMaitre Vascular, Inc. | ||
|---|---|---|
| Date: April 29, 2021 | By: | Joseph P. Pellegrino, Jr. |
| /s/ JOSEPH P. PELLEGRINO, JR. | ||
| Joseph P. Pellegrino, Jr. | ||
| Chief Financial Officer |
ex_244915.htm
Exhibit 99.1
LeMaitre Q1 2021 Financial Results
BURLINGTON, MA, April 29, 2021 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2021 results and announced an $0.11/share quarterly dividend.
Q1 2021 Results
| ● | Sales of $35.9mm, +17% (-5% organic) vs. Q1 2020 |
|---|---|
| ● | Op. income of $7.9mm, +83% |
| --- | --- |
| ● | Op. margin of 22% |
| --- | --- |
| ● | Net income of $5.9mm, +87% |
| --- | --- |
| ● | Earnings of $0.28 per diluted share, +83% |
| --- | --- |
| ● | EBITDA of $10.5mm, +83% |
| --- | --- |
| ● | Debt paid down $7.0mm to $32.0mm |
| --- | --- |
Sales grew in the Americas (+29%) and Asia/Pac (+25%) while Europe/Middle East/Africa (-5%) declined. Sales growth was led by Artegraft, valvulotomes and embolectomy catheters, and was partially offset by CE Mark and COVID related issues.
The gross margin decreased to 66.3% in Q1 2021 (vs. 67.0% in Q1 2020) primarily due to factory transitions and manufacturing inefficiencies. Operating expenses decreased 2% to $15.9mm in Q1 2021 (vs. $16.1mm) due to lower headcount and decreased travel.
George LeMaitre, Chairman and CEO, said, “Double-digit sales growth and restrained expenses enabled 83% bottom-line growth. And our 22% op. margin enabled us to improve the balance sheet.”
Business Outlook
| Guidance | |
|---|---|
| Q2 2021 Sales | $37.0mm - $40.0mm<br><br> <br>(Midpoint: $38.5mm, +55%) |
| Q2 2021 Gross Margin | 66.7% |
| Q2 2021 Operating Income | $8.0mm - $10.0mm<br><br> <br>(Midpoint: $9.0mm, +85%) |
| Q2 2021 Earnings Per Share | $0.28 - $0.36<br><br> <br>(Midpoint: $0.32, +86%) |
Quarterly Dividend
On April 27, 2021, the Company's Board of Directors approved a quarterly dividend of $0.11/share of common stock. The dividend will be paid on June 3, 2021 to shareholders of record on May 19, 2021.
Share Repurchase Program
On February 23, 2021, the Company's Board of Directors authorized the repurchase of up to $15.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 22, 2022, unless extended by the Board.
Conference Call Reminder
Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company's website at www.lemaitre.com/investor. The conference call may also be accessed by dialing 844-239-5284 (+1 512-961-6497 for international callers), using passcode 7316629. For individuals unable to join the live conference call, a replay will be available on the Company's website.
A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.
About LeMaitre
LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.
LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.
For more information about the Company, please visit http://www.lemaitre.com.
Use of Non-GAAP Financial Measures
LeMaitre Vascular management believes that in order to better understand the Company's short-term and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.
In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events as well as EBITDA or earnings before interest, taxes, depreciation and amortization. The Company refers to the calculation of non-GAAP sales growth percentages as "organic." The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events, and EBITDA to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. The Company believes that evaluating EBITDA provides an approximation of the cash generating ability of its operations.
The Company has also reported non-GAAP outstanding debt, which takes into account the impact of unamortized deferred financing costs. The Company believes that considering its debt in this manner provides a view of the amount owed on a cash basis.
Forward-Looking Statements
The Company's current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, the status of our global regulatory approvals and compliance with foreign regulatory requirements to market and sell our products outside the United States; the duration of the lapse in CE mark approval for certain of our devices; the final closure of an audit by one of our notified bodies in support of the issuance and/or maintenance of CE marks covering certain of our products or the failure of such audit to be successfully closed; the duration and severity of the impact of COVID-19 on the global economy, our customers, our suppliers and our company; the risk of significant fluctuations in our quarterly and annual results due to numerous factors; the risk that assumptions about the market for the Company’s products and the productivity of the Company’s direct sales force and distributors may not be correct; the risk that we may not be able to maintain our recent levels of profitability; the risk that the Company may not realize the anticipated benefits of its strategic activities; risks related to the integration of acquisition targets; the acceleration or deceleration of product growth rates; risks related to product demand and market acceptance of the Company’s products and pricing; the risk that a recall of our products could result in significant costs or negative publicity; the risk that the Company is not successful in transitioning to a direct-selling model in new territories and other risks and uncertainties included under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
| LEMAITRE VASCULAR, INC (NASDAQ: LMAT) | ||||||
|---|---|---|---|---|---|---|
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
| (amounts in thousands) | ||||||
| March 31, 2021 | December 31, 2020 | |||||
| --- | --- | --- | --- | --- | --- | --- |
| (unaudited) | ||||||
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 23,525 | $ | 26,764 | ||
| Short-term marketable securities | 214 | 214 | ||||
| Accounts receivable, net | 20,126 | 19,552 | ||||
| Inventory and other deferred costs | 45,071 | 45,115 | ||||
| Prepaid expenses and other current assets | 1,721 | 2,618 | ||||
| Total current assets | 90,657 | 94,263 | ||||
| Property and equipment, net | 15,200 | 15,036 | ||||
| Right-of-use leased assets | 15,478 | 16,066 | ||||
| Goodwill | 65,945 | 65,945 | ||||
| Other intangibles, net | 57,339 | 58,905 | ||||
| Deferred tax assets | 1,640 | 1,686 | ||||
| Other assets | 1,110 | 909 | ||||
| Total assets | $ | 247,369 | $ | 252,810 | ||
| Liabilities and stockholders' equity | ||||||
| Current liabilities: | ||||||
| Current portion of long-term debt | $ | 2,750 | $ | 2,500 | ||
| Accounts payable | 2,561 | 2,394 | ||||
| Accrued expenses | 14,365 | 17,525 | ||||
| Acquisition-related obligations | 776 | 772 | ||||
| Lease liabilities - short-term | 1,848 | 1,954 | ||||
| Total current liabilities | 22,300 | 25,145 | ||||
| Long-term debt | 28,485 | 35,532 | ||||
| Lease liabilities - long-term | 14,360 | 14,791 | ||||
| Deferred tax liabilities | 124 | 127 | ||||
| Other long-term liabilities | 4,575 | 4,643 | ||||
| Total liabilities | 69,844 | 80,238 | ||||
| Stockholders' equity | ||||||
| Common stock | 221 | 221 | ||||
| Additional paid-in capital | 117,236 | 114,924 | ||||
| Retained earnings | 74,221 | 70,554 | ||||
| Accumulated other comprehensive loss | (2,463 | ) | (1,525 | ) | ||
| Treasury stock | (11,690 | ) | (11,602 | ) | ||
| Total stockholders' equity | 177,525 | 172,572 | ||||
| Total liabilities and stockholders' equity | $ | 247,369 | $ | 252,810 |
| LEMAITRE VASCULAR, INC (NASDAQ: LMAT) | ||||||
|---|---|---|---|---|---|---|
| CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS | ||||||
| (amounts in thousands, except per share amounts) | ||||||
| (unaudited) | ||||||
| For the three months ended | ||||||
| --- | --- | --- | --- | --- | --- | --- |
| March 31, 2021 | March 31, 2020 | |||||
| Net sales | $ | 35,883 | $ | 30,551 | ||
| Cost of sales | 12,084 | 10,068 | ||||
| Gross profit | 23,799 | 20,483 | ||||
| Operating expenses: | ||||||
| Sales and marketing | 6,466 | 7,945 | ||||
| General and administrative | 6,544 | 5,191 | ||||
| Research and development | 2,844 | 2,994 | ||||
| Total operating expenses | 15,854 | 16,130 | ||||
| Income from operations | 7,945 | 4,353 | ||||
| Other income: | ||||||
| Interest income | 1 | 105 | ||||
| Interest expense | (577 | ) | - | |||
| Foreign currency gain (loss) | 124 | (178 | ) | |||
| Income before income taxes | 7,493 | 4,280 | ||||
| Provision for income taxes | 1,564 | 1,106 | ||||
| Net income | $ | 5,929 | $ | 3,174 | ||
| Earnings per share of common stock | ||||||
| Basic | $ | 0.29 | $ | 0.16 | ||
| Diluted | $ | 0.28 | $ | 0.16 | ||
| Weighted - average shares outstanding: | ||||||
| Basic | 20,546 | 20,168 | ||||
| Diluted | 20,847 | 20,438 | ||||
| Cash dividends declared per common share | $ | 0.110 | $ | 0.095 |
| LEMAITRE VASCULAR, INC (NASDAQ: LMAT) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SELECTED NET SALES INFORMATION | ||||||||||
| (amounts in thousands) | ||||||||||
| (unaudited) | ||||||||||
| For the three months ended | ||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 31, 2021 | March 31, 2020 | |||||||||
| **** | $ | % | **** | $ | % | |||||
| Net Sales by Geography | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
| Americas | $ | 23,699 | 66 | % | $ | 18,336 | 60 | % | ||
| Europe/Middle East/Africa | 9,862 | 27 | % | 10,350 | 34 | % | ||||
| Asia/Pacific Rim | 2,322 | 7 | % | 1,865 | 6 | % | ||||
| Total Net Sales | $ | 35,883 | 100 | % | $ | 30,551 | 100 | % | ||
| LEMAITRE VASCULAR, INC (NASDAQ: LMAT) | ||||||||||
| --- | ||||||||||
| NON-GAAP FINANCIAL MEASURES | ||||||||||
| (amounts in thousands) | ||||||||||
| (unaudited) | ||||||||||
| Reconciliation between GAAP and Non-GAAP sales growth: | ||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||
| For the three months ended March 31, 2021 | ||||||||||
| Net sales as reported | $ | 35,883 | ||||||||
| Impact of currency exchange rate fluctuations | (947 | ) | ||||||||
| Net impact of acquisitions excluding currency | (5,832 | ) | ||||||||
| Adjusted net sales | $ | 29,104 | ||||||||
| For the three months ended March 31, 2020 | ||||||||||
| Net sales as reported | $ | 30,551 | ||||||||
| Adjusted net sales | $ | 30,551 | ||||||||
| Adjusted net sales decrease for the three months ended March 31, 2021 | $ | (1,447 | ) | -5 | % | |||||
| Reconciliation between GAAP and non-GAAP debt outstanding: | ||||||||||
| As of March 31, 2021 | ||||||||||
| Debt as reported | $ | 31,235 | ||||||||
| Add back unamortized deferred financing costs | 765 | |||||||||
| Adjusted debt outstanding | $ | 32,000 | ||||||||
| For the three months ended | ||||||||||
| --- | --- | --- | --- | --- | --- | |||||
| March 31, 2021 | March 31, 2020 | |||||||||
| Reconciliation between GAAP and Non-GAAP EBITDA | ||||||||||
| Net income as reported | $ | 5,929 | $ | 3,174 | ||||||
| Interest (income) expense, net | 576 | (105 | ) | |||||||
| Amortization and depreciation expense | 2,388 | 1,538 | ||||||||
| Provision for income taxes | 1,564 | 1,106 | ||||||||
| EBITDA | $ | 10,457 | $ | 5,713 | ||||||
| EBITDA percentage increase | 83 | % |